Hess, D

Hitz, F; Kraus, M; Pabst, Thomas; Hess, D; Besse, L; Silzle, T; Novak, Urban; Seipel, Katja; Rondeau, S; Stüdeli, S; Vilei, S Berardi; Samaras, P; Mey, U; Driessen, C (2019). Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10). Blood cancer journal, 9(9), p. 70. Springer Nature 10.1038/s41408-019-0228-2

Pagani, O; Klingbiel, D; Ruhstaller, T; Nolè, F; Eppenberger, S; Oehlschlegel, C; Bernhard, Jürg; Brauchli, P; Hess, D; Mamot, C; Munzone, E; Pestalozzi, B; Rabaglio, Manuela; Aebi, S; Ribi, K; Rochlitz, C; Rothgiesser, K; Thürlimann, B; von Moos, R; Zaman, K; ... (2017). Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99. Annals of oncology, 28(2), pp. 305-312. Oxford University Press 10.1093/annonc/mdw622

Hess, D; Koberle, D; Thurlimann, B; Pagani, O; Schonenberger, A; Mattmann, S; Rochlitz, C; Rauch, D; Schuller, J C; Ballabeni, P; Ribi, K (2007). Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99). Onkologie, 73(3-4), pp. 228-37. Basel: Karger 10.1159/000180915